JP2014513065A5 - - Google Patents

Download PDF

Info

Publication number
JP2014513065A5
JP2014513065A5 JP2013557757A JP2013557757A JP2014513065A5 JP 2014513065 A5 JP2014513065 A5 JP 2014513065A5 JP 2013557757 A JP2013557757 A JP 2013557757A JP 2013557757 A JP2013557757 A JP 2013557757A JP 2014513065 A5 JP2014513065 A5 JP 2014513065A5
Authority
JP
Japan
Prior art keywords
composition
subject
compound
administration
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013557757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014513065A (ja
Filing date
Publication date
Priority claimed from US13/041,211 external-priority patent/US20120225922A1/en
Application filed filed Critical
Publication of JP2014513065A publication Critical patent/JP2014513065A/ja
Publication of JP2014513065A5 publication Critical patent/JP2014513065A5/ja
Withdrawn legal-status Critical Current

Links

JP2013557757A 2011-03-04 2012-02-28 （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法 Withdrawn JP2014513065A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/041,211 US20120225922A1 (en) 2011-03-04 2011-03-04 Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
US13/041,211 2011-03-04
PCT/US2012/026984 WO2012154285A1 (en) 2011-03-04 2012-02-28 Effective amounts of (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017231910A Division JP2018076332A (ja) 2011-03-04 2017-12-01 （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法

Publications (2)

Publication Number Publication Date
JP2014513065A JP2014513065A (ja) 2014-05-29
JP2014513065A5 true JP2014513065A5 (https=) 2015-04-09

Family

ID=46753679

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013557757A Withdrawn JP2014513065A (ja) 2011-03-04 2012-02-28 （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法
JP2017231910A Pending JP2018076332A (ja) 2011-03-04 2017-12-01 （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017231910A Pending JP2018076332A (ja) 2011-03-04 2017-12-01 （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法

Country Status (10)

Country Link
US (9) US20120225922A1 (https=)
EP (1) EP2683242B8 (https=)
JP (2) JP2014513065A (https=)
KR (1) KR20140019361A (https=)
CN (1) CN103582419A (https=)
AU (1) AU2012254093B2 (https=)
BR (1) BR112013022673A2 (https=)
CA (1) CA2829039C (https=)
DK (1) DK2683242T3 (https=)
WO (1) WO2012154285A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225922A1 (en) * 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
US12042482B2 (en) * 2015-08-14 2024-07-23 Annovis Bio, Inc. Methods of treatment or prevention of acute brain or nerve injuries
US20180338950A1 (en) 2017-05-24 2018-11-29 Qr Pharma, Inc. Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis Via Administration of Posiphen to Healthy or Sick Humans
WO2020061404A1 (en) * 2018-09-21 2020-03-26 Aristea Translational Medicine Corporation Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions
SG11202103794QA (en) 2018-11-21 2021-05-28 Ionis Pharmaceuticals Inc Compounds and methods for reducing prion expression
WO2021067864A1 (en) * 2019-10-02 2021-04-08 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for treatment of prion disease
WO2022245843A1 (en) * 2021-05-18 2022-11-24 Annovis Bio, Inc. Inhibition of neurological injuries due to infections via administration of butanetap and analogs thereof
EP4486892A2 (en) * 2022-02-28 2025-01-08 Ionis Pharmaceuticals, Inc. Rnai agents of prion expression
WO2024123663A1 (en) * 2022-12-06 2024-06-13 Sri International Antimicrobial compounds
EP4731205A2 (en) * 2023-06-21 2026-04-29 Annovis Bio, Inc. Solid forms of posiphen d-tartrate
WO2025017530A1 (en) 2023-07-19 2025-01-23 Assia Chemical Industries Ltd. Solid state forms of buntanetap and process for preparation thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171750A (en) 1991-09-26 1992-12-15 The United States Of America As Represented By The Department Of Health And Human Services Substituted phenserines as specific inhibitors of acetylcholinesterase
US5409948A (en) * 1992-11-23 1995-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating cognitive disorders with phenserine
CZ297533B6 (cs) 1997-07-09 2007-01-03 Axonyx Použití inhibitorů butyrylcholinesterázy pro léčbu a diagnostiku Alzheimerovy choroby a demence
EP1311272B1 (en) 2000-03-03 2006-11-22 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
US7153882B2 (en) * 2000-11-02 2006-12-26 The United States Of America As Represented By The Department Of Health And Human Services Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
WO2003024450A1 (en) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
US6495700B1 (en) 2002-01-09 2002-12-17 Axonyx, Inc. Process for producing phenserine and its analog
US20040024043A1 (en) * 2002-03-22 2004-02-05 Nigel Greig Method for treating cognitive disorders
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004087160A1 (en) 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
US20050013869A1 (en) * 2003-07-18 2005-01-20 Chaw Cheng Shu Sustained release formulation for carbamates and a method therefor
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
WO2005089746A1 (en) * 2004-03-19 2005-09-29 Axonyx, Inc. Dosage titration for treatment of cognitive disorders
JP2007529545A (ja) 2004-03-19 2007-10-25 アクソニクス，インコーポレイテッド ダウン症候群の治療法
WO2005123068A2 (en) 2004-06-08 2005-12-29 Axonyx, Inc. Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
WO2008134618A2 (en) 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders
WO2008153884A1 (en) * 2007-06-07 2008-12-18 Dynogen Pharmaceuticals, Inc. Compositions useful for treating gastroesophageal reflux disease
JP4690362B2 (ja) * 2007-07-04 2011-06-01 株式会社リコー Ｓｉｍｄ型マイクロプロセッサおよびｓｉｍｄ型マイクロプロセッサのデータ転送方法
WO2010117727A2 (en) * 2009-03-30 2010-10-14 The General Hospital Corporation Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions
US20120225922A1 (en) * 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration

Similar Documents

Publication Publication Date Title
JP2014513065A5 (https=)
JP2014528914A5 (https=)
JP2014517050A5 (https=)
NZ751418A (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
GB201104267D0 (en) Pyrrolopyridineamino derivatives
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
HK1247093A1 (zh) 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法
JP2014514349A5 (https=)
NZ598137A (en) Oxazine derivatives and their use in the treatment of neurological disorders
WO2015191506A3 (en) Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
JP2009533356A5 (https=)
HK1198869A1 (en) Combination treatments for hepatitis c
MX2021011563A (es) Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen.
WO2014070991A3 (en) Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
FI3865484T3 (fi) Pde9:n estäjä, jossa on imidatsopyratsinonirunko, perifeeristen sairauksien hoitoon
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2015522018A5 (https=)
PH12013501098A1 (en) Pharmaceutical compositions
JP2016512247A5 (https=)
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
RU2016103098A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii